Platelet‐derived growth factor (PDGF) in type 1 diabetes mellitus

Guillausseau, P. J.; Dupuy, Évelyne; Bryckaert, Marijke; Timsit, José; Chanson, P.; Tobelem, Gérard; Caen, Jacques P.; Lubetzki, J

doi:10.1111/j.1365-2362.1989.tb00213.x

Cited by 25 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelets from diabetic patients have demonstrated reduced mitogenic activity for fibroblasts, and it has been proposed that this is due to loss of platelet PDGF in to the plasma [3,4]. Such release could impair the ability of platelets to initiate healing, and accelerate the development of diabetic complications such as angiopathy by increasing plasma-borne PDGF [3,4].…”

Section: Discussionmentioning

confidence: 99%

“…Such release could impair the ability of platelets to initiate healing, and accelerate the development of diabetic complications such as angiopathy by increasing plasma-borne PDGF [3,4]. Previous assays of PDGF concentrations in diabetic patients have lacked suitability or sensitivity for use in plasma [4,5]. An ELI-SA with a detection limit of 2 ng/ml detected PDGF in the plasma of only one of 28 diabetic patients [5].…”

Section: Discussionmentioning

confidence: 99%

“…In diabetes mellitus, abnormalities in platelet function have frequently been observed, but while enhanced platelet aggregation responses have been a consistent finding, reports of altered release of platelet constituents have been more controversial [2]. Some previous work has shown that the platelets of diabetic patients contain less fibroblast mitogenic activity than platelets from control subjects, and it has been proposed that platelets from patients with diabetes release PDGF prematurely [3,4]. The resulting platelet PDGF deficit might contribute to the delayed healing seen in diabetes [3], while increased plasma PDGF concentrations could be involved in Subjects with NIDDM were significantly older than the other two groups, p < .001 Table 2.…”

mentioning

confidence: 99%

“…Severe LJM normal, a equivocal or unilateral findings one or two interphalangeal joints or one large joint or only metacarpophalangeal joints bilaterally three or more interphalangeal joints or one finger joint and one large joint bilaterally moderate limitation combined with cervical spine involvement or hand deformity at rest a Where normal ranges of movement are defined as greater than or equal to: 180 ~ extension at the proximal interphalangeal joints 60 ~ extension at metacarpophalangeal joints 70 ~ extension at the wrist 180 ~ extension at the elbow 100 ~ flexion at the ankle 35 ~ lateral flexion at the cervical and thoracolumbar spine other complications of diabetes such as angiopathy [4]. However, plasma PDGF concentrations have not been measured in diabetic patients with a sensitive specific assay [4,5].…”

mentioning

confidence: 99%

“…However, plasma PDGF concentrations have not been measured in diabetic patients with a sensitive specific assay [4,5]. In the current study a sensitive ELISA has been used to assess PDGF concentrations in the plasma and serum in patients with both insulin-dependent diabetes (IDDM) and non-insulin dependent diabetes (NIDDM).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Immunoassay of platelet-derived growth factor in the blood of patients with diabetes mellitus

1994

View full text Add to dashboard Cite

Summary Platelet-derived growth factor (PDGF) is a powerful mitogen for many cell types, and is believed to play a major role in wound healing when released from platelets at sites of injury. In diabetes mellitus, it has been proposed that premature release of PDGF from platelets impairs the ability of platetets to initiate healing, and also accelerates the development of diabetic complications such as angiopathy by increasing plasma-borne PDGE However, plasma samples from diabetic patients have not previously been assayed for PDGF using suitable techniques. A sensitive monoclonal enzyme-linked immunoassay for PDGF was applied to plasma and serum samples fiom 18 healthy control subjects and 60 diabetic patients. Neither plasma nor serum PDGF concentrations differed significantly between control subjects, insulin-dependent, and non-insulin-dependent diabetic patients. However, 23 % of the diabetic subjects had serum PDGF levels above the control range. Limited joint mobility, which is characterised by joint contractures and collagen deposition in the skin, and is associated with microvascular disease, was used as a marker of diabetic complications. Limited joint mobility affected 43 % of the diabetic subjects. Patients with moderate limited joint mobility bad had diabetes significantly longer than those without limited joint mobility (means 17years and 9 years, respectively, p = 0.008). However, limited joint mobility was not associated with elevated serum or plasma PDGF in insulin-dependent or non-insulin-dependent diabetes. We conclude that complications of diabetes are unlikely to be caused by changes in systemic levels of PDGE The delayed healing associated with diabetes is not due to a deficit in PDGF available from platelets. [Diabetologia (1994[Diabetologia ( ) 37: 1142[Diabetologia ( -1146

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations